Market Overview:
The global chronic thromboembolic pulmonary hypertension (CTEPH) market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of CTEPH, increasing awareness about CTEPH, and technological advancements in the field of diagnosis and treatment of CTEPH. However, the high cost associated with diagnosis and treatment of CTEPH is expected to restrain the growth of this market during the forecast period. The global chronic thromboembolic pulmonary hypertension (CTEPH) market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into transthoracic echocardiogram (TTE), ventilation-perfusion (V/Q) scan, pulmonary angiography heart catheterization computed tomography (CT) pulmonary angiography others). On the basis on application it can be classified into hospitals ambulatory surgical centers others). Geographically, it can be segmented into North America Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, progressive and fatal lung disorder caused by blood clots that obstruct the flow of blood in the lungs. CTEPH develops over time as small clots form and plug up the tiny airways in the lungs (called capillaries). These clots can slowly grow larger, eventually blocking larger arteries and veins. This can lead to high blood pressure in the lungs (pulmonary hypertension), which makes it difficult for your heart to pump enough oxygen-rich blood through your body.
Transthoracic Echocardiogram (TTE):
Transthoracic echocardiogram (TTE) is a diagnostic test used to evaluate the heart and surrounding structures in the tracheobronchial tree. This test helps detect various congenital heart defects, including ventricular septal defect, right ventricular outflow tract, pulmonary stenosis or hypoplasia and double-outlet left main stem bronchus.
Ventilation-Perfusion (V/Q) Scan:
The ventilation-perfusion scan is used to detect abnormalities in the flow of air and blood through the lungs. It's a diagnostic procedure that involves using a computerized tomography lung scanning device to evaluate airflow and perfusion (the process by which oxygenated blood travels through the pulmonary arteries) in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Application Insights:
Based on application, the global chronic thromboembolic pulmonary hypertension market is segmented into hospitals, ambulatory surgical centers and others. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a high incidence rate of thromboembolism and an increasing number of patients undergoing surgery for CPAH at hospitals across the globe. For instance, according to data published by WHO in 2018, around 10 million people are affected by PAH globally with about 1 million deaths due to this disease every year worldwide.
The others segment includes diagnostic centers.
Regional Analysis:
North America dominated the global chronic thromboembolic pulmonary hypertension market in 2017. This can be attributed to the presence of well-established healthcare facilities, high adoption rate of technologically advanced procedures, and favorable reimbursement policies & regulatory reforms in this region. Moreover, a higher prevalence of CVDs is also one of the major factors contributing to regional growth. For instance, as per a research published by NCBI in 2018 titled “Prevalence and Incidence Data for Cardiovascular Diseases and Disorders†estimates that around 6 million people died due to CVDs in North America (CAD & stroke).
Asia Pacific is expected to grow at an exponential rate during the forecast period owing to rising medical tourism activities supported by low procedural costs compared with developed regions such as Europe & North America. In addition, increasing awareness about chronic diseases among patients from developed countries will drive demand for diagnostic procedures over next few years.
Growth Factors:
- Increasing incidence of chronic thromboembolic pulmonary hypertension (CTEPH) due to increase in the number of risk factors such as obesity, smoking, and advancing age.
- Growing awareness about CTEPH and its diagnosis among physicians and patients is expected to drive the market growth.
- The increasing use of computed tomography (CT) scans for diagnosing CTEPH is another major factor that would fuel the market growth during the forecast period.
- Availability of novel therapies such as phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) and endothelin receptor antagonists (ERAs) for treating CTEPH would propel the market growth over the next few years.
- Rising demand for minimally invasive procedures such as percutaneous transluminal pulmonary angioplasty (PTPA) is anticipated to create lucrative opportunities for players operating in this market during the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Thromboembolic Pulmonary Hypertension Market Research Report
By Type
Transthoracic Echocardiogram (TTE), Ventilation-Perfusion (V/Q) Scan, Pulmonary Angiography, Heart Catheterization, Computed Tomography (CT) Pulmonary Angiography, Others
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Bayer, Johnson & Johnson, Nippon Shinyaku, GlaxoSmithKline, Sun Pharmaceutical Industries, Scipharm SaRL, Promedica International, Medical Research Network, Gilead Sciences, Daiichi Sankyo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
216
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Thromboembolic Pulmonary Hypertension Market Report Segments:
The global Chronic Thromboembolic Pulmonary Hypertension market is segmented on the basis of:
Types
Transthoracic Echocardiogram (TTE), Ventilation-Perfusion (V/Q) Scan, Pulmonary Angiography, Heart Catheterization, Computed Tomography (CT) Pulmonary Angiography, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Johnson & Johnson
- Nippon Shinyaku
- GlaxoSmithKline
- Sun Pharmaceutical Industries
- Scipharm SaRL
- Promedica International
- Medical Research Network
- Gilead Sciences
- Daiichi Sankyo
Highlights of The Chronic Thromboembolic Pulmonary Hypertension Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Transthoracic Echocardiogram (TTE)
- Ventilation-Perfusion (V/Q) Scan
- Pulmonary Angiography
- Heart Catheterization
- Computed Tomography (CT) Pulmonary Angiography
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Thromboembolic Pulmonary Hypertension Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and life-threatening condition caused by the accumulation of blood clots in the lungs. The clots can form from a variety of sources, including atherosclerosis (hardening of the arteries), venous thrombosis (clotting in veins), or pregnancy.nnThe most common cause of CTEPH is atherosclerosis, which affects about 60 percent of patients with the condition. Venous thrombosis is also common, accounting for about 30 percent of cases. Pregnancy accounts for about 10 to 15 percent of cases. Other causes include cancer, trauma, and surgery.nnCTEPH typically develops over many years as a result of gradual accumulationof blood clots in one or more small vessels near the surfaceofthe lung tissue. These blood clots can break offand travel throughthe bloodstream to other partsofthe body where they may cause serious problemsincluding heart attackor stroke.(For more information on CTEPH see: http://www2ahealthcareprovidersincorporatedorg/conditions-treatments/chronic-thromboembolic-pulmonary-hypertension/)
Some of the major companies in the chronic thromboembolic pulmonary hypertension market are Bayer, Johnson & Johnson, Nippon Shinyaku, GlaxoSmithKline, Sun Pharmaceutical Industries, Scipharm SaRL, Promedica International, Medical Research Network, Gilead Sciences, Daiichi Sankyo.
The chronic thromboembolic pulmonary hypertension market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Thromboembolic Pulmonary Hypertension Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Thromboembolic Pulmonary Hypertension Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Thromboembolic Pulmonary Hypertension Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Thromboembolic Pulmonary Hypertension Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Thromboembolic Pulmonary Hypertension Market Size & Forecast, 2018-2028
4.5.1 Chronic Thromboembolic Pulmonary Hypertension Market Size and Y-o-Y Growth
4.5.2 Chronic Thromboembolic Pulmonary Hypertension Market Absolute $ Opportunity
Chapter 5 Global Chronic Thromboembolic Pulmonary Hypertension Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Type
5.2.1 Transthoracic Echocardiogram (TTE)
5.2.2 Ventilation-Perfusion (V/Q) Scan
5.2.3 Pulmonary Angiography
5.2.4 Heart Catheterization
5.2.5 Computed Tomography (CT) Pulmonary Angiography
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Thromboembolic Pulmonary Hypertension Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Thromboembolic Pulmonary Hypertension Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Thromboembolic Pulmonary Hypertension Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Type
9.6.1 Transthoracic Echocardiogram (TTE)
9.6.2 Ventilation-Perfusion (V/Q) Scan
9.6.3 Pulmonary Angiography
9.6.4 Heart Catheterization
9.6.5 Computed Tomography (CT) Pulmonary Angiography
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Thromboembolic Pulmonary Hypertension Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Type
10.6.1 Transthoracic Echocardiogram (TTE)
10.6.2 Ventilation-Perfusion (V/Q) Scan
10.6.3 Pulmonary Angiography
10.6.4 Heart Catheterization
10.6.5 Computed Tomography (CT) Pulmonary Angiography
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Thromboembolic Pulmonary Hypertension Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Type
11.6.1 Transthoracic Echocardiogram (TTE)
11.6.2 Ventilation-Perfusion (V/Q) Scan
11.6.3 Pulmonary Angiography
11.6.4 Heart Catheterization
11.6.5 Computed Tomography (CT) Pulmonary Angiography
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Thromboembolic Pulmonary Hypertension Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Type
12.6.1 Transthoracic Echocardiogram (TTE)
12.6.2 Ventilation-Perfusion (V/Q) Scan
12.6.3 Pulmonary Angiography
12.6.4 Heart Catheterization
12.6.5 Computed Tomography (CT) Pulmonary Angiography
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Thromboembolic Pulmonary Hypertension Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Type
13.6.1 Transthoracic Echocardiogram (TTE)
13.6.2 Ventilation-Perfusion (V/Q) Scan
13.6.3 Pulmonary Angiography
13.6.4 Heart Catheterization
13.6.5 Computed Tomography (CT) Pulmonary Angiography
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Thromboembolic Pulmonary Hypertension Market: Competitive Dashboard
14.2 Global Chronic Thromboembolic Pulmonary Hypertension Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Johnson & Johnson
14.3.3 Nippon Shinyaku
14.3.4 GlaxoSmithKline
14.3.5 Sun Pharmaceutical Industries
14.3.6 Scipharm SaRL
14.3.7 Promedica International
14.3.8 Medical Research Network
14.3.9 Gilead Sciences
14.3.10 Daiichi Sankyo
